Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity.
BACKGROUND
Detrusor overactivity is often observed in patients with multiple sclerosis (MS), and neurotoxins are emerging as second-line therapies albeit with different degrees of success per patient basis.


OBJECTIVE
To investigate lower urinary tract (LUT) functional status and bladder innervation (calcitonin gene related peptide [CGRP] and substance P [SP] positive nerve fibers) in patients with MS.


METHODS
Eighteen MS patients with LUT symptoms underwent urodynamic investigations, and six non-MS patients undergoing cystoscopy due to microscopic hematuria served as controls. Cold cut bladder biopsies were taken from the bladder trigone region. Neurotransmitter expression was determined by individual immunohistochemical staining.


RESULTS
Two distinct groups could be distinguished: group 1 with pronounced neurogenic detrusor overactivity and mild outflow obstruction; group 2 with some degree of neurogenic detrusor overactivity, detrusor hypocontractility during voiding, and high degree of an outflow obstruction. The presence of SP and CGRP immunoreactive + fiber density was observed in greater numbers in group 1.


CONCLUSIONS
Density of CGRP and SP positive nerve fibers within the urinary bladder of patients with MS may be suggestive of functional status of the lower urinary tract, namely denser innervation is observed in patients with mild outflow obstruction and strong detrusor overactivity. This observation could be useful when planning second-line treatment (neurotoxins) in these patients. Patients with denser innervation probably will respond better to such a therapy.
Radziszewski
P
P
Department and Clinic of Urology, Faculty of Medical Sciences, Medical Academy in Warsaw, Poland. pradziszewski@neostrada.pl
Crayton
R
R
Zaborski
J
J
Członkowska
A
A
Borkowski
A
A
Bossowska
A
A
Majewski
M
M
D000328:Adult; D001706:Biopsy; D015740:Calcitonin Gene-Related Peptide / Q000032:analysis*; D016022:Case-Control Studies; D003558:Cystoscopy; D005260:Female; D006417:Hematuria / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009103:Multiple Sclerosis / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D009434:Neural Pathways / Q000378:metabolism / Q000503:physiopathology; D011984:Sensory Receptor Cells / Q000737:chemistry*; D013373:Substance P / Q000032:analysis*; D001743:Urinary Bladder / Q000294:innervation*; D053201:Urinary Bladder, Overactive / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology*; D014563:Urodynamics; D019459:Urothelium / Q000294:innervation
D013373:Substance P; D015740:Calcitonin Gene-Related Peptide